Back to News
Market Impact: 0.3
LENZ Therapeutics Q3 Earnings Call Highlights
Source: marketbeat.com
Corporate EarningsHealthcare & BiotechProduct LaunchesCompany Fundamentals
LENZ Therapeutics reported third-quarter 2026 VIZZ product revenue of $2.6 million, up 50% sequentially. The company attributed prescription growth to expanded national advertising and the launch of a telehealth channel.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
LENZ0.60
More News
- DoorDash offers $17 billion for Instacart: ‘the largest companies are only eating more and more of the pie’
- Alphabet Erases $500 Billion as ChatGPT, Google AI Cut into Search
- Alphabet just had its worst day as a public company. BofA now values Google search at a lower multiple than fossil fuel stocks
- Norwegian shares surge 13% on earnings beat, guidance raise
- Taiwan Stocks Heads for Correction as Global AI Selloff Deepens
- Asia stocks tumble as AI spending concerns deepen; BOJ holds rates